TG Therapeutics Secures $750 Million Credit Facility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy TGTX?
Source: NASDAQ.COM
- Expanded Financing: TG Therapeutics announced a new five-year $750 million senior secured credit facility managed by Blue Owl Capital, expected to provide $500 million in non-dilutive capital, enhancing financial flexibility to support future R&D initiatives.
- Debt Repayment Strategy: The new credit facility will be utilized to repay the existing $250 million senior secured credit, ensuring the company can reduce its financial burden while leveraging additional funds for strategic investments and operational expansion.
- Increased Share Repurchase Program: The company has been authorized to increase its share repurchase program from $100 million to $300 million, demonstrating confidence in its stock value and helping to enhance shareholder returns while boosting market expectations for future growth.
- Positive Market Reaction: Following the financing announcement, TG Therapeutics shares rose 1.70% in pre-market trading on Nasdaq to $30.55 per share, reflecting investor optimism regarding the company's financial health and strategic direction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TGTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TGTX
Wall Street analysts forecast TGTX stock price to rise
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 31.980
Low
15.00
Averages
43.50
High
60.00
Current: 31.980
Low
15.00
Averages
43.50
High
60.00
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TG Therapeutics Secures $750 Million Credit Facility
- Expanded Financing: TG Therapeutics announced a new five-year $750 million senior secured credit facility managed by Blue Owl Capital, expected to provide $500 million in non-dilutive capital, enhancing financial flexibility to support future R&D initiatives.
- Debt Repayment Strategy: The new credit facility will be utilized to repay the existing $250 million senior secured credit, ensuring the company can reduce its financial burden while leveraging additional funds for strategic investments and operational expansion.
- Increased Share Repurchase Program: The company has been authorized to increase its share repurchase program from $100 million to $300 million, demonstrating confidence in its stock value and helping to enhance shareholder returns while boosting market expectations for future growth.
- Positive Market Reaction: Following the financing announcement, TG Therapeutics shares rose 1.70% in pre-market trading on Nasdaq to $30.55 per share, reflecting investor optimism regarding the company's financial health and strategic direction.
See More
TG Therapeutics Secures $750M Credit Facility
- Expanded Financing: TG Therapeutics has entered into a new five-year, $750 million senior secured credit facility with Blue Owl Capital, successfully repaying its previous $250 million credit facility, resulting in a net capital raise of $500 million that significantly strengthens the company's capital structure.
- Increased Capital Flexibility: The new credit agreement allows TG to access up to an additional $250 million of incremental capital at mutual discretion, raising the total facility size to $1 billion, thereby providing greater flexibility for future strategic investments.
- Stock Buyback Program Expansion: The company's board has authorized an increase in its stock repurchase program from $100 million to $300 million, reflecting confidence in the company's future performance while also creating additional value for shareholders.
- Buyback Progress: As of March 18, 2026, TG has repurchased approximately $38 million of common stock under the existing buyback program at an average price of $28.98 per share, indicating proactive measures in capital management.
See More
ACT Capital Management Acquires Stake in TG Therapeutics
- New Investment Position: On February 17, 2026, ACT Capital Management disclosed a new position by acquiring 268,875 shares of TG Therapeutics for $8,015,164, reflecting confidence in the company's future potential.
- Asset Allocation Insight: This acquisition represents 6.5% of ACT's total reportable U.S. equity assets of $123.67 million, indicating a strategic focus on the biotechnology sector, particularly in oncology and immunology markets.
- Performance Metrics: TG Therapeutics achieved product sales of approximately $606.9 million in 2025, nearly doubling year-over-year, which propelled total revenue to about $616.3 million, showcasing the rapid growth of its core product BRIUMVI in treating multiple sclerosis.
- Market Outlook: The company targets global revenue of $875 million to $900 million for 2026, and if it exceeds these projections, it could trigger a stock price rebound, suggesting that ACT's investment strategy may be betting on this potential market recovery.
See More
Precision BioSciences Unveils PBGENE-HBV Clinical Data at AASLD
- Clinical Trial Progress: The Phase 1 data for PBGENE-HBV presented at AASLD indicates that 13 patients have been treated across the first five cohorts, demonstrating good safety and tolerability, with dose-dependent antiviral activity, marking a significant advancement in chronic hepatitis B treatment.
- Successful Fundraising: The company raised $75 million in November 2025, extending its cash runway through 2028 to support multiple clinical inflection points for PBGENE-HBV and PBGENE-DMD, enhancing financial stability.
- IND Approval and New Trial Launch: PBGENE-DMD received IND clearance from the FDA in 2026, allowing the initiation of the Phase 1/2 FUNCTION-DMD clinical trial, with initial data from multiple patients expected by year-end 2026, further advancing treatment for Duchenne muscular dystrophy.
- Enhanced Patent Protection: In March 2026, the company received two Notices of Allowance related to PBGENE-HBV, extending patent expiration to 2044, ensuring competitive advantage in hepatitis B treatment.
See More
BRIUMVI Shows Significant Efficacy in Highly Active Relapsing Multiple Sclerosis
- Clinical Trial Results: In the ULTIMATE I and II Phase 3 trials, BRIUMVI demonstrated significant efficacy in 168 patients with highly active relapsing multiple sclerosis, achieving an annualized relapse rate of 0.145 at 96 weeks compared to 0.496 for teriflunomide, representing a 70.8% reduction (P<0.001), indicating its critical potential in controlling disease progression.
- Reduction in MRI Activity: At Week 12, BRIUMVI reduced the least squares mean number of Gd+ T1 lesions by 83.3% (0.114 vs 0.683; P<0.001), and over 96 weeks, Gd+ T1 lesions decreased by 95.6% (0.038 vs 0.875; P<0.001), demonstrating effective control of disease activity radiologically.
- Increased NEDA-3 Rates: BRIUMVI achieved a NEDA-3 rate of 29.5% at Week 12 compared to 10.1% for teriflunomide (OR [95% CI], 4.716 [1.847–12.046]; P=0.001), with rates rising to 77.9% versus 16.4% during Weeks 24-96, underscoring the importance of early treatment.
- Therapeutic Regimen Advantage: BRIUMVI's administration involves a 150mg IV infusion followed by 450mg two weeks later and every 24 weeks, showcasing its feasibility and advantages in effectively treating patients with relapsing multiple sclerosis, supporting early intervention to mitigate disease progression risks.
See More
TG Therapeutics Announces BRIUMVI® Presentation Schedule at AAN 2026
- Presentation Schedule: TG Therapeutics will showcase BRIUMVI® (ublituximab-xiiy) data for patients with relapsing forms of multiple sclerosis at the 2026 American Academy of Neurology annual meeting, scheduled for April 21, 2026, which is expected to attract industry attention and enhance the company's visibility in this field.
- Research Findings: The presentation will highlight real-world clinical experiences from the ENABLE study, focusing on the effects of BRIUMVI in patients with relapsing multiple sclerosis, which is anticipated to provide crucial data support for clinical practice and further drive market acceptance of BRIUMVI.
- Safety Updates: The ENHANCE study will offer updates on the safety and tolerability of a modified dosing regimen for BRIUMVI, which is expected to bolster physician confidence in the drug, thereby promoting its clinical application.
- Market Potential: As a monoclonal antibody targeting CD20, BRIUMVI has received approvals in the U.S. and several other countries, expected to address the treatment needs of over 2.3 million multiple sclerosis patients worldwide, further solidifying TG Therapeutics' market position in the biopharmaceutical sector.
See More
TG Therapeutics Secures $750 Million Credit Facility
- Expanded Financing: TG Therapeutics announced a new five-year $750 million senior secured credit facility managed by Blue Owl Capital, expected to provide $500 million in non-dilutive capital, enhancing financial flexibility to support future R&D initiatives.
- Debt Repayment Strategy: The new credit facility will be utilized to repay the existing $250 million senior secured credit, ensuring the company can reduce its financial burden while leveraging additional funds for strategic investments and operational expansion.
- Increased Share Repurchase Program: The company has been authorized to increase its share repurchase program from $100 million to $300 million, demonstrating confidence in its stock value and helping to enhance shareholder returns while boosting market expectations for future growth.
- Positive Market Reaction: Following the financing announcement, TG Therapeutics shares rose 1.70% in pre-market trading on Nasdaq to $30.55 per share, reflecting investor optimism regarding the company's financial health and strategic direction.
See More
TG Therapeutics Secures $750M Credit Facility
- Expanded Financing: TG Therapeutics has entered into a new five-year, $750 million senior secured credit facility with Blue Owl Capital, successfully repaying its previous $250 million credit facility, resulting in a net capital raise of $500 million that significantly strengthens the company's capital structure.
- Increased Capital Flexibility: The new credit agreement allows TG to access up to an additional $250 million of incremental capital at mutual discretion, raising the total facility size to $1 billion, thereby providing greater flexibility for future strategic investments.
- Stock Buyback Program Expansion: The company's board has authorized an increase in its stock repurchase program from $100 million to $300 million, reflecting confidence in the company's future performance while also creating additional value for shareholders.
- Buyback Progress: As of March 18, 2026, TG has repurchased approximately $38 million of common stock under the existing buyback program at an average price of $28.98 per share, indicating proactive measures in capital management.
See More
ACT Capital Management Acquires Stake in TG Therapeutics
- New Investment Position: On February 17, 2026, ACT Capital Management disclosed a new position by acquiring 268,875 shares of TG Therapeutics for $8,015,164, reflecting confidence in the company's future potential.
- Asset Allocation Insight: This acquisition represents 6.5% of ACT's total reportable U.S. equity assets of $123.67 million, indicating a strategic focus on the biotechnology sector, particularly in oncology and immunology markets.
- Performance Metrics: TG Therapeutics achieved product sales of approximately $606.9 million in 2025, nearly doubling year-over-year, which propelled total revenue to about $616.3 million, showcasing the rapid growth of its core product BRIUMVI in treating multiple sclerosis.
- Market Outlook: The company targets global revenue of $875 million to $900 million for 2026, and if it exceeds these projections, it could trigger a stock price rebound, suggesting that ACT's investment strategy may be betting on this potential market recovery.
See More
Precision BioSciences Unveils PBGENE-HBV Clinical Data at AASLD
- Clinical Trial Progress: The Phase 1 data for PBGENE-HBV presented at AASLD indicates that 13 patients have been treated across the first five cohorts, demonstrating good safety and tolerability, with dose-dependent antiviral activity, marking a significant advancement in chronic hepatitis B treatment.
- Successful Fundraising: The company raised $75 million in November 2025, extending its cash runway through 2028 to support multiple clinical inflection points for PBGENE-HBV and PBGENE-DMD, enhancing financial stability.
- IND Approval and New Trial Launch: PBGENE-DMD received IND clearance from the FDA in 2026, allowing the initiation of the Phase 1/2 FUNCTION-DMD clinical trial, with initial data from multiple patients expected by year-end 2026, further advancing treatment for Duchenne muscular dystrophy.
- Enhanced Patent Protection: In March 2026, the company received two Notices of Allowance related to PBGENE-HBV, extending patent expiration to 2044, ensuring competitive advantage in hepatitis B treatment.
See More
BRIUMVI Shows Significant Efficacy in Highly Active Relapsing Multiple Sclerosis
- Clinical Trial Results: In the ULTIMATE I and II Phase 3 trials, BRIUMVI demonstrated significant efficacy in 168 patients with highly active relapsing multiple sclerosis, achieving an annualized relapse rate of 0.145 at 96 weeks compared to 0.496 for teriflunomide, representing a 70.8% reduction (P<0.001), indicating its critical potential in controlling disease progression.
- Reduction in MRI Activity: At Week 12, BRIUMVI reduced the least squares mean number of Gd+ T1 lesions by 83.3% (0.114 vs 0.683; P<0.001), and over 96 weeks, Gd+ T1 lesions decreased by 95.6% (0.038 vs 0.875; P<0.001), demonstrating effective control of disease activity radiologically.
- Increased NEDA-3 Rates: BRIUMVI achieved a NEDA-3 rate of 29.5% at Week 12 compared to 10.1% for teriflunomide (OR [95% CI], 4.716 [1.847–12.046]; P=0.001), with rates rising to 77.9% versus 16.4% during Weeks 24-96, underscoring the importance of early treatment.
- Therapeutic Regimen Advantage: BRIUMVI's administration involves a 150mg IV infusion followed by 450mg two weeks later and every 24 weeks, showcasing its feasibility and advantages in effectively treating patients with relapsing multiple sclerosis, supporting early intervention to mitigate disease progression risks.
See More
TG Therapeutics Announces BRIUMVI® Presentation Schedule at AAN 2026
- Presentation Schedule: TG Therapeutics will showcase BRIUMVI® (ublituximab-xiiy) data for patients with relapsing forms of multiple sclerosis at the 2026 American Academy of Neurology annual meeting, scheduled for April 21, 2026, which is expected to attract industry attention and enhance the company's visibility in this field.
- Research Findings: The presentation will highlight real-world clinical experiences from the ENABLE study, focusing on the effects of BRIUMVI in patients with relapsing multiple sclerosis, which is anticipated to provide crucial data support for clinical practice and further drive market acceptance of BRIUMVI.
- Safety Updates: The ENHANCE study will offer updates on the safety and tolerability of a modified dosing regimen for BRIUMVI, which is expected to bolster physician confidence in the drug, thereby promoting its clinical application.
- Market Potential: As a monoclonal antibody targeting CD20, BRIUMVI has received approvals in the U.S. and several other countries, expected to address the treatment needs of over 2.3 million multiple sclerosis patients worldwide, further solidifying TG Therapeutics' market position in the biopharmaceutical sector.
See More
